Cell and Gene Therapy Bioprocessing Market to Soar to USD 14.8 Billion by 2035 at 11.2% CAGR
Accelerating regulatory approvals and manufacturing scale-up initiatives propel the global cell and gene therapy bioprocessing sector into a decade of transformative growth and technological convergence.
NEW YORK, September 8, 2026 — The global Cell and Gene Therapy Bioprocessing Market was valued at an estimated USD 5.1 Billion in 2025 and is projected to reach USD 5.7 Billion in 2026, according to Healthcare Industry Insights. The market is forecast to expand significantly to USD 14.8 Billion by 2035, demonstrating a robust compound annual growth rate (CAGR) of 11.2% between 2026 and 2035. This substantial growth trajectory is primarily attributed to accelerating regulatory approvals for advanced cell and gene therapies, increasing adoption across core application sectors including oncology and rare genetic disorders, and technological advancements across product architectures spanning bioreactor systems, filtration platforms, and automated manufacturing solutions.
North America anchored the market with an estimated dominant share in 2026, reflecting its advanced infrastructure, established regulatory frameworks, and early adoption of next-generation bioprocessing capabilities. Meanwhile, Asia-Pacific is projected to emerge as the fastest-growing region, driven by rapid industrial modernization, expanding contract manufacturing organization (CMO) footprints, and supportive government initiatives aimed at positioning regional economies as global cell and gene therapy manufacturing hubs.
The cell and gene therapy bioprocessing sector represents one of the most dynamic and capital-intensive segments within the broader biopharmaceutical manufacturing landscape. Unlike conventional small-molecule and monoclonal antibody production, cell and gene therapy manufacturing demands specialized infrastructure, highly trained personnel, and sophisticated quality assurance protocols to ensure patient safety and therapeutic efficacy. The market's expansion reflects not only the growing clinical pipeline of approved therapies but also the industry's collective commitment to de-risking manufacturing processes, reducing production costs, and scaling capacity to meet anticipated demand across global patient populations.
Key Findings
- The Cell and Gene Therapy Bioprocessing Market is set to expand from USD 5.7 Billion in 2026 to USD 14.8 Billion by 2035, growing at an 11.2% CAGR. This expansion represents an absolute dollar opportunity of approximately USD 9.1 Billion over the forecast period, reflecting sustained capital investment and operational scaling across the sector.
- The dominant segment—encompassing closed-system bioreactors and single-use bioprocessing platforms—led the market in 2026, owing to established deployment scale, technological maturity, and demonstrated cost-effectiveness relative to legacy open-system architectures. Single-use systems, in particular, have gained significant traction due to their reduced contamination risk, lower capital requirements, and operational flexibility in supporting multiple product candidates within shared manufacturing facilities.
- The fastest-growing sub-segment is projected to expand at an outsized CAGR from 2026 to 2035, driven by accelerating modernization initiatives and the emergence of next-generation automated systems capable of real-time process monitoring and adaptive control. These advanced platforms integrate artificial intelligence and machine learning algorithms to optimize cell culture conditions, predict process deviations, and enhance overall manufacturing consistency.
- Core enterprise applications—including CAR-T cell therapies, autologous cell therapies, and in vivo gene therapies—represented the largest end-use category in 2026, reflecting widespread mission-critical adoption among leading biopharmaceutical companies and specialized contract manufacturers. The therapeutic diversity within this category underscores the market's resilience and its capacity to support multiple therapeutic modalities simultaneously.
- North America led the market in 2026, while Asia-Pacific is forecast to be the fastest-growing region through 2035, with compound annual growth rates exceeding 17 percent. This regional divergence reflects both the maturity of North American manufacturing infrastructure and the aggressive capacity expansion strategies being pursued by emerging Asian economies, particularly China, India, and South Korea.
- The market presents an absolute dollar growth opportunity of billions between 2026 and 2035, with particular concentration in equipment sales, consumables, and specialized services including process development, analytical support, and regulatory consulting.
What Is Driving Growth in the Cell and Gene Therapy Bioprocessing Market?
Based on Healthcare Industry Insights's proprietary research and primary source interviews with 47 industry stakeholders, the largest single contributor to the market's forecast growth is accelerating regulatory approvals and clinical pipeline expansion, an effect estimated to add roughly 2.4 percentage points to the CAGR through 2035. The FDA, EMA, and other regulatory authorities have demonstrated increasing confidence in cell and gene therapy manufacturing processes, resulting in expedited approval pathways and reduced time-to-market for qualified candidates. This regulatory momentum has directly translated into increased capital allocation toward manufacturing infrastructure and bioprocessing technology development.
A closely related catalyst is accelerating technological innovation and system modernization, which is estimated to contribute an additional 1.8 percentage points to the market's CAGR. Innovations in perfusion bioreactors, continuous bioprocessing platforms, and integrated downstream purification systems are enabling manufacturers to achieve higher cell densities, improved product quality, and reduced manufacturing timelines. These technological advances are particularly critical for therapies targeting large patient populations, where traditional batch-based manufacturing approaches would prove economically unsustainable.
Growth is tempered, however, by supply chain complexities and regulatory compliance friction. Healthcare Industry Insights's analysis indicates that this restraint reduces the CAGR by an estimated 1.1 percentage points. Supply chain vulnerabilities—particularly in specialized consumables, raw materials, and analytical reagents—have emerged as a material constraint on manufacturing capacity expansion. Additionally, the evolving regulatory landscape, characterized by increasing scrutiny of manufacturing controls and product characterization requirements, has extended development timelines and increased operational costs for market participants.
An emerging opportunity lies in next-generation architectures and automated digital integration, opening high-margin revenue streams and driving long-term market expansion through 2035. The convergence of bioprocessing technology with digital manufacturing platforms, cloud-based data analytics, and advanced process control systems is creating new value propositions for equipment manufacturers and enabling contract manufacturers to differentiate on operational efficiency and product quality metrics.
Regional Snapshot
Analyst Commentary
"This assessment is reinforced by shifting capital expenditure patterns, where leading Tier-1 biopharmaceutical companies and technology vendors are actively reallocating resources toward automated, resilient, and next-generation product architectures. Strategic partnerships between equipment manufacturers and contract manufacturers are accelerating the commercialization of integrated bioprocessing solutions that address the full manufacturing workflow from cell expansion through final product formulation."
Latest Developments in the Cell and Gene Therapy Bioprocessing Market
In recent developments, leading market participants announced breakthrough platform deployments, engineered with advanced performance features to improve operational reliability, reduce manufacturing timelines, and enhance product consistency. These systems incorporate real-time process monitoring, predictive analytics, and automated control mechanisms designed to minimize human intervention and reduce the risk of process deviations.
Industry primes completed strategic manufacturing and technological capacity expansions to meet surging demand across core regional channels. Notable investments include facility expansions in North Carolina, Singapore, and the European Union, reflecting geographic diversification strategies aimed at reducing supply chain risk and improving market proximity to key customer bases.
Key innovators formed multi-party collaborations and partnerships to accelerate the commercialization of sustainable and high-efficiency systems. These partnerships span equipment manufacturers, contract manufacturers, academic research institutions, and regulatory consulting firms, creating integrated ecosystems designed to de-risk manufacturing scale-up and accelerate time-to-market for novel therapies.
About Healthcare Industry Insights
Healthcare Industry Insights is a premier market research and consulting firm delivering syndicated research reports, custom studies, and strategic advisory services across high-growth industries worldwide. Every Healthcare Industry Insights study adheres to rigorous analytical standards: single-point defensible estimates, MECE segmentation, exact table reconciliation, and verified primary sources. The firm's research methodology combines quantitative market modeling with qualitative stakeholder interviews, ensuring comprehensive market coverage and actionable strategic insights.
Media Contact
Press Office, Healthcare Industry Insights ✉️ press@healthcareindustryinsights.com 🌐 healthcareindustryinsights.com
Release Tags: New Report · Cell and Gene Therapy Bioprocessing Market · Industry Intelligence